

Minerva Neurosciences (NERV : US\$5.55)

Minerva Neurosciences sinks 9% in 2015

Minerva Neurosciences Inc., NASDAQ's 47th largest Healthcare-Products company by market cap, sank 56.0c (or 9.2%) year to date in 2015 to close at US\$5.55. Compared with the NASDAQ-100 Index which has risen 4.8% YTD, this is a relative price change of -13.9%. The volume YTD has been 1.4 times the average trading of 97,550 shares. In 2015 the market cap has declined US\$9.3 million.

Introduction with Trends

We are currently bullish on this stock in the short-term based on technical indicators, but are more bearish in the long-term based on fundamental metrics

What makes us most bullish on the stock is the following:

- It is beating 82% of the market the past 6 months.
- The price to 50-day EMAP ratio is 1.1, a bullish indicator. The 50-day EMAP has increased to US\$5.19.

stock Summary

Sector	Healthcare-Products
Market Cap	US\$102.3 million
Shares Outstanding	18,439,482
ISIN	US6033801068
Relative Strength (3 mo)	65

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	5.6	102.3 million

Analysis

Bullish Signals

- In the last 2 trading sessions there has been a net rise of 6.5%; the stock has advanced nine times and the biggest one day rise was 8% on Jun 08.
- In the NASDAQ market of 2,382 stocks and 3 units traded today, the stock has a 6-month relative strength of 82 which means it is beating 82% of the market.
- A price rise combined with a high relative strength is a bullish signal.
- The stock traded at a two-month high of US\$5.60 today.

Undervaluation:

- The company is cash rich with Cash to Market Capitalisation at 18.1%.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 1.5. Compared with the rest of the market the stock is undervalued.

Other Bullish Signals:

Also, the following criteria set by Benjamin Graham:

- "Current ratio of two or more"; current assets are 5.5 times current liabilities.

Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	8.0	In Top 3%
Relative Strength (6M)	82	In Top Quartile
%Prem To Vol Wtd Price	7.0	In Top Quartile

Bearish Signals

- The price is at a premium of 7.0% to the 1-month volume weighted average price of US\$5.19. Given that this premium has been under 7.0% one hundred ninety-nine times and over 7.0% thirty-two times in the last year, the downside:upside probability is estimated at 199:32 or 6.2:1.
- Falls to Rises: In the last three months the number of falls outnumbered rises 34:27 or 1.26:1.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 5.13 minus the 26-day EMA of 5.15 is negative suggesting a bearish signal.
- The Price/MAP of 0.64 for NERV is lower than the Price/MAP for the NASDAQ-100 Index of 1.0.

- The price to 200-day MAP ratio is 0.64, a bearish indicator. In the past 200 days this ratio has been under 0.64 53 times suggesting further downside. The stock is trading below both its MAPs at US\$8.61 for the 200-day MAP and US\$9.78 for the 50-day MAP, another bearish indicator.
- The price has risen above the upper Bollinger band of US\$5.33; the stock is also overbought according to the Williams % R indicator of -6.3.
- The current short volume is 2.4 times its own historical average of 0.1%. It climbed 4.0% from the previous day, increased 1.3% from a week ago and soared 5,660.9% from a month ago, a significant bearish indicator.

Other Bearish Signals:

The stock has a score of merely 1 out of 9 set by Joseph Piotroski [pass mark ≥ 5]:

Improvement in current ratio from 1.3 to 5.5.

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$102.3 million	In Bottom Quartile
Price/MAP200	0.64	In Bottom 9%
Price/MAP50	0.57	In Bottom 8%
Volatility %	13.6	In Bottom 3%

Note

Neutral Indicators and Rank in Market:


Description	Value	Rank In Market
Turnover in Quarter	US\$25.1 million	In 3rd Quartile

Insider Trades



Analysis (continued)

Turnover Rate & Turnover Period




Trailing 3 months

Turnover US\$25.1 million


Volume 4,417,702

Volume Index (1 is avg) 0.7

Weekly Price Volume Dynamics (Last 12 Weeks)




Relative Strength



Price/Moving Avg Price [P/MAP200]



stock v Index (Trailing Year)



Peer Group Analysis

Name	Last Price	Relative Str. (6-months)	MCap (USD)	PV \$1000 (1 yr)	Revenue (USD)	Net Profit (USD)	Total Assets (USD)
MediWound	US\$5.61	29	119.5M	464		(8.5M)	14.8M
Galmed Pharmaceutical	US\$10.07	97	111.8M	1,379		(17.5M)	170,000
Conatus Pharmaceuticals	US\$5.61	11	110.6M	1,012		(22.3M)	38.4M
Minerva Neurosciences	US\$5.55	82	102.3M			(56.9M)	68.5M
Achaogen	US\$5.67	4	102.2M	412	20M	(20.2M)	70.3M
Bio Blast Pharma	US\$5.93	17	84.4M				
Scynexis	US\$8.89	31	75.1M	1,052	19M	(5.9M)	39.7M

Reported Buying by Directors

Director	Date	Transaction Type	No. of Shares	Price, USD	Value, USD
De Rubertis Francesco	Mar 18, 2015	Bought	202,634	4.81	974,670
Ollier Michele	Mar 18, 2015	Bought	202,634	4.81	974,670

Company Overview

Activities

Minerva Neurosciences Inc. operates as a clinical-stage biopharmaceutical company. The Company develops new therapies to treat central nervous system (CNS) and neuropsychiatric diseases and disorders. Minerva Neurosciences serves communities in the United States.

Further details can be found at
<http://www.minervaneurosciences.com>.

Economic Sector	Healthcare
Business Sector	Healthcare Services
Industry Group	Healthcare Equipment & Supplies

Regulatory Announcements

Conferences/Exhibitions

May 28: Minerva Neurosciences To Present At Upcoming Investor Conferences In June

[News Story] WALTHAM, Mass., May 28, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases and disorders, today announced that it will participate in the following upcoming investor conferences:

Live audio webcasts will be available online from the investor relations section of the company's website at <http://ir.minervaneurosciences.com>.

[For more details click here.](#)

Board and Management

May 18: Minerva Neurosciences appoints Director

Minerva Neurosciences has appointed Fouzia Laghrissi-Thode as a Director. The effective date is May 18, 2015.

Key Developments

May 07: Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates

[News Story]

MIN-101 Phase 2b trial for schizophrenia on track with enrollment underway; new regulatory approvals to conduct trials in Europe

MIN-117 Phase 2a study in Major Depressive Disorder (MDD) on track and expected to begin enrollment in second quarter; additional study arm planned

Management to host conference call today at 8:30 a.m.

[For more details click here.](#)

Conferences/Exhibitions

April 30: Events Calendar: Minerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call

WALTHAM, Mass., April 30, 2015 -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases and disorders, today announced that it will release first quarter 2015 financial results before markets open on Thursday, May 7, 2015.

[For more details click here.](#)

Directors Option Buying

April 16: Minerva Neurosciences director awarded Stock Options

Minerva Neurosciences (NASDAQ:NERV) director Luthringer Remy, has been awarded Stock Options on 399,623 shares at an exercise price of US\$5.19. The transaction date was April 14, 2015. The shares last traded at US\$5.83.

Directors Option Buying

April 16: Minerva Neurosciences insider awarded Stock Options

Minerva Neurosciences (NASDAQ:NERV) insider Race Geoff, has been awarded Stock Options on 213,133 shares at an exercise price of US\$5.19. The transaction date was April 14, 2015. The shares last traded at US\$5.83.

Directors Option Buying

April 16: Minerva Neurosciences insider awarded Stock Options

Minerva Neurosciences (NASDAQ:NERV) insider Reilly Joseph H., has been awarded Stock Options on 57,524 shares at an exercise price of US\$5.19. The transaction date was April 14, 2015. The shares last traded at US\$5.83.

8-K people news

November 06: Minerva Neurosciences appoints Remy Luthringer as president 07 November 2014

Minerva Neurosciences has appointed Remy Luthringer as President. The appointment takes effect from Nov 05, 2014.

8-K other news

March 26: Minerva Neurosciences: Results of Operations and Financial Condition

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515106926_0001193125-15-106926.txt

Source: 8-K United States Securities and Exchange Commission

Company Overview (continued)

March 18: Minerva Neurosciences: Entry into a Material Definitive Agreement

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515096955_0001193125-15-096955.txt

Source: 8-K United States Securities and Exchange Commission

March 13: Minerva Neurosciences: Regulation FD Disclosure

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515090350_0001193125-15-090350.txt

Source: 8-K United States Securities and Exchange Commission

March 03: Minerva Neurosciences: Other Events

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515074284_0001193125-15-074284.txt

Source: 8-K United States Securities and Exchange Commission

January 21: Minerva Neurosciences: Other Events

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515016250_0001193125-15-016250.txt

Source: 8-K United States Securities and Exchange Commission

January 20: Minerva Neurosciences: Entry into a Material Definitive Agreement

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515014828_0001193125-15-014828.txt

Source: 8-K United States Securities and Exchange Commission

January 05: Minerva Neurosciences: Other Events

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312515001733_0001193125-15-001733.txt

Source: 8-K United States Securities and Exchange Commission

December 03: Minerva Neurosciences: Other Events

[News Story]

http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1598646_000119312514431523_0001193125-14-431523.txt

Source: 8-K United States Securities and Exchange Commission

Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

Issued Capital

Based on 18,439,482 issued equity shares the market capitalisation is US\$102.3 million.


The top twenty shareholders hold 51.1% of the issued capital leaving a float of 48.9%.

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Fmr Llc	2,765,922	15
Federated Investors Inc /Pa/	2,506,611	13.59
Cormorant Asset Management Llc	1,145,043	6.21
Perceptive Advisors Llc	810,537	4.4
Armistice Capital Llc	202,634	1.1
Dafna Capital Management Llc	101,317	0.55
Spark Investment Management Llc	57,079	0.31
Vanguard Group Inc	53,195	0.29
Goldman Sachs Group Inc	29,702	0.16
Kcg Holdings Inc.	17,881	0.1
Total	7,689,921	41.7

Company Overview (continued)

Top 20 Institutional Holdings



Board and Management



Geoff Race
CFO & Executive Vice President

Prior to being named as Minerva Neurosciences' CFO, Mr. Race served as a consultant for the development of MIN-101 and MIN-117. He has previously served as Chief Executive Officer of Funxional Therapeutics Ltd., the lead program of which (FX125L) was acquired by Boehringer Ingelheim in 2012. He also served as Chief Financial Officer at PanGenetics B.V. He is a Fellow of the Chartered Institute of Management Accountants and earned his MBA from Durham University Business School.

Marc D. Beer
Chairman

Remy Luthringer
CEO & President

Creation of shareholder value in Minerva Neurosciences:

Since appointment as President: The present value of USD1,000 invested on the appointment date of November 05, 2014 at close price of US\$4.35 is US\$1,276, for a capital gain of US\$276.

Fouzia Laghrissi-Thode
Director

Dr. Laghrissi-Thode has nearly 20 years of experience in the pharmaceutical industry, and has held positions of leadership at AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease and genito-urinary health. She is currently vice president of the cardiovascular and metabolism therapy area at AstraZeneca. Her business development and licensing accomplishments include demonstrated successes in global product strategy, franchise development and expansion, collaborations, corporate partnerships and joint ventures. Dr. Laghrissi-Thode holds an M.D. from the University of Tours School of Medicine in France, is board certified in psychiatry and is adjunct professor of psychiatry at the University of Pittsburgh.


Creation of shareholder value in Minerva Neurosciences:

Since appointment as Director: The present value of USD1,000 invested on the appointment date of May 18, 2015 at close price of US\$5.06 is US\$1,097, for a capital gain of US\$97.



Joseph Reilly
Chief Operating Officer & Vice President

Joe Reilly was most recently Vice President, Head of Commercial Strategy and Operations at Genzyme Corporation. In more than a decade at Genzyme, he also served as Vice President of Global Business Operations, Vice President of Commercial Operations and Vice President of Finance in the Rare Diseases Division. Joe holds a BS and MS in Finance from Boston College.



Mark Levine
Vice President & General Counsel

Mark Levine has extensive experience counseling companies on general corporate matters, complex commercial transactions, mergers and acquisitions, securities law, corporate governance and regulatory compliance. Prior to joining Minerva Neurosciences in 2014, he served in senior legal positions at athenahealth, Inc., Clinical Data, Inc., Wheelabrator Technologies Inc., and Xpedior Incorporated. He holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor degree from Washington University School of Law in St. Louis.

Fred Ahlholm
Vice President & Chief Accounting Officer

Fred Ahlholm was most recently Vice President of Finance and Chief Accounting Officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. Fred is a CPA and earned his BBA at the University of Notre Dame.

Francesco De Rubertis
Director-Index Ventures

Jan Van Heek
Director

Michele Ollier
Director-Index Ventures

Financials

Annual Report for the year ended December 31, 2014

year-on-year comparisons with previous corresponding period

Favourable Changes

- Total liabilities to total assets down 19.4% to 0.2.

Unfavourable Changes

- Net tangible assets per share down 1.7% to \$US2.88
- Operating cash flow is negative.

Major Common Size Ratios

- Total current assets to total assets up from 6.2% to 28.3%
- Cash to total assets up from 6.2% to 27.1%
- Intangibles to total assets down from 27.1% to 21.7%.

Financial Results (Annual)

31 December, 2014

INCOME STATEMENT

Currency in USD	2014-12-31	2013-12-31	Change %
Expenses			
Research and development	42,908,566	708,489	Up 5,956.3
General and administrative	11,961,865	2,466,490	Up 385.0
Total expenses	54,870,431	3,174,979	Up 1,628.2
Loss from operations	-54,870,431	-3,174,979	Deterioration 1,628.2
Foreign exchange gains -losses	18,727	-28,977	Recovery
Interest -expense income	2,049,735	58,049	Up 3,431.0
Net loss	-56,901,439	-3,262,005	Deterioration 1,644.4
Net loss per share, basic and diluted	-447.0c	-78.0c	Deterioration 473.1
Weighted average shares outstanding, basic and diluted	12,724,395	4,186,104	Up 204.0

BALANCE SHEET

Currency in USD	2014-12-31	2013-12-31	Change %
Assets			
Current assets			
Cash and cash equivalents	18,545,702	1,818,317	Up 919.9
Restricted cash	35,014		
Prepaid expenses	756,979	852	Up 88,747.3
Total current assets	19,337,695	1,819,169	Up 963.0
Equipment, net	43,446	3,232	Up 1,244.2
In-process research and development	34,200,000	19,000,000	Up 80.0
Goodwill	14,869,399	7,918,387	Up 87.8
Deferred public offering costs		433,998	
Total assets	68,450,540	29,174,786	Up 134.6
Liabilities and Stockholders' Equity			
Current liabilities			
Accounts payable	641,813	522,981	Up 22.7
Accrued expenses and other current liabilities	1,645,258	815,239	Up 101.8
Accrued collaborative expenses	1,222,420		
Convertible promissory notes		58,270	
Derivative liability		10,093	
Total current liabilities	3,509,491	1,406,583	Up 149.5
Deferred taxes	13,433,760	7,588,600	Up 77.0
Other noncurrent liabilities	7,694		
Total liabilities	16,950,945	8,995,183	Up 88.4
Commitments and contingencies			
Stockholders' equity			

Financial Results (Annual) (continued)

31 December, 2014

Preferred stock;.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of December 31, 2014 and 2013, respectively

Common stock;.0001 par value; 125,000,000 shares authorized; 1,844,18,439,482 and 6,112,738 shares issued and outstanding as of December 31, 2014 and 2013, respectively

Additional paid-in capital	126,228,981	38,008,783	Up 232.1
Accumulated deficit	-74,731,230	-17,829,791	Deterioration 319.1
Total stockholders' equity	51,499,595	20,179,603	Up 155.2
Total liabilities and stockholders' equity	68,450,540	29,174,786	Up 134.6

CASH FLOW

Currency in USD	2014-12-31	2013-12-31	Change %
Cash flows from operating activities:			
Net loss	-56,901,439	-3,262,005	Deterioration 1,644.4
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	33,869		
Amortization of debt discount recorded as interest expense	1,952,309	36,231	Up 5,288.5
Stock-based compensation expense	17,966,611	655,723	Up 2,640.0
Unrealized foreign exchange loss		22,039	
Change in fair value of derivative	-10,093	117	Deterioration
Changes in operating assets and liabilities			
Prepaid expenses	-713,200	8,143	Deterioration
Accounts payable	368,698	522,981	Down 29.5
Accrued expenses and other liabilities	112,285	-143,472	Recovery
Accrued collaborative expenses	1,222,420		
Other noncurrent liabilities	7,694		
Net cash used in operating activities	-35,960,846	-2,160,243	Deterioration 1,564.7
Cash flows from investing activities:			
Cash acquired in business combination	1,167,869		
Restricted cash	-35,014		
Purchases of equipment	-45,609	-3,232	Deterioration 1,311.2
Net cash provided by investing activities	1,087,246	-3,232	Recovery
Cash flows from financing activities:			
Cash acquired in business merger		631,478	
Proceeds from issuance of convertible promissory notes		1,300,000	
Proceeds from working capital loans	1,882,817		
Repayments of working capital loans	-1,882,817		
Proceeds from sales of common stock in initial public offering	31,334,702		

Financial Results (Annual) (continued)

31 December, 2014

Proceeds from sales of common stock in private placements	23,706,118	1,850,000	Up 1,181.4
Fees paid in connection with private placements	-280,000		
Public offering costs paid	-3,159,835		
Net cash provided by financing activities	51,600,985	3,781,478	Up 1,264.6
Net increase in cash and cash equivalents	16,727,385	1,618,003	Up 933.8
Cash and cash equivalents			
Beginning of period	1,818,317	200,314	Up 807.7
End of period	18,545,702	1,818,317	Up 919.9

PERFORMANCE RATIOS

	2014-12-31	2013-12-31	Change %
Return on Equity (%)	-110.49	-16.16	
Return on Assets (%)	-83.13	-11.18	
Total Liabilities to Operating Cash Flow	-0.47	-4.16	Reduced 88.7
Total Liabilities/Total Assets	0.25	0.31	Down 19.7
Current Ratio	5.51	1.29	

PER SHARE FIGURES

	2014-12-31	2013-12-31	Change %
Cash	US\$1.46	43.44c	Up 235.5
Working Capital	US\$1.24	9.86c	
Shareholders' Funds	US\$4.05	US\$4.82	Down 16.0
Total Liabilities	US\$1.33	US\$2.15	Down 38.0
Total Assets	US\$5.38	US\$6.97	Down 22.8
Net Tangible Assets	US\$2.88	US\$2.93	Down 1.7
EPS Final	-447.0c	-78.0c	

Glossary

Return on Equity (Shareholders' Funds):

Net Profit/Net Assets (%)

Price Close/Moving Av Price:

Latest Price/Moving Average Price

Current Ratio:

Current Assets/Current Liabilities (times)

Cash/Mcap:

Cash plus Liquids/Market Capitalisation (times)

Moving Average Price (n periods):

Sum of Prices for each Period/Number of Periods

Return on Assets:

Net Profit/Total Assets (%)

Total Liabilities/Total Assets:

Total Liabilities/Total Assets

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews “hot tip” or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.